Details of the Drug

General Information of Drug (ID: DMZ4P3A)

Drug Name
Telithromycin
Synonyms
Ketek; Levviax; TEL; HMR 3647; HMR3647; RU 66647; RU66647; HMR-3647; Ketek (TN); RU-66647; Telithromycin [USAN:BAN:INN]; Telithromycin (JAN/USAN/INN); (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 812
Topological Polar Surface Area (xlogp) 4.2
Rotatable Bond Count (rotbonds) 11
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 13
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability
57% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [4]
Elimination
13% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [4]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 14.0742 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.41% [4]
Vd
The volume of distribution (Vd) of drug is 2.9 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.8 mg/mL [2]
Chemical Identifiers
Formula
C43H65N5O10
IUPAC Name
(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-methoxy-1,5,7,9,11,13-hexamethyl-15-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
Canonical SMILES
CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C
InChI
InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1
InChIKey
LJVAJPDWBABPEJ-PNUFFHFMSA-N
Cross-matching ID
PubChem CID
3002190
ChEBI ID
CHEBI:29688
CAS Number
191114-48-4
DrugBank ID
DB00976
TTD ID
D09HNR
VARIDT ID
DR00576
INTEDE ID
DR1544
ACDINA ID
D00656

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA) TTUWYEA NOUNIPROTAC Binder [8], [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [10]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Telithromycin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Clarithromycin. Bacterial infection [1A00-1C4Z] [57]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Telithromycin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [57]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Telithromycin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [58]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [59]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Norfloxacin. Bacterial infection [1A00-1C4Z] [60]
Rabeprazole DMMZXIW Moderate Decreased metabolism of Telithromycin caused by Rabeprazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [61]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Levofloxacin. Bacterial infection [1A00-1C4Z] [59]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [57]
⏷ Show the Full List of 8 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Telithromycin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Telithromycin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [60]
Clindamycin DM15HL8 Moderate Increased metabolism of Telithromycin caused by Clindamycin mediated induction of CYP450 enzyme. Acne vulgaris [ED80] [62]
Metreleptin DM1NOEK Moderate Increased metabolism of Telithromycin caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [61]
Ivosidenib DM8S6T7 Major Decreased metabolism of Telithromycin caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [63]
Midostaurin DMI6E0R Major Decreased metabolism of Telithromycin caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [64]
Idarubicin DMM0XGL Moderate Decreased clearance of Telithromycin due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [65]
Arn-509 DMT81LZ Major Increased metabolism of Telithromycin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [66]
Gilteritinib DMWQ4MZ Major Decreased metabolism of Telithromycin caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [67]
Oliceridine DM6MDCF Major Decreased metabolism of Telithromycin caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [68]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Telithromycin and Rivastigmine. Alzheimer disease [8A20] [57]
Ivabradine DM0L594 Major Decreased metabolism of Telithromycin caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [60]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Telithromycin and Bepridil. Angina pectoris [BA40] [69]
Dronedarone DMA8FS5 Major Decreased metabolism of Telithromycin caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [60]
Nifedipine DMSVOZT Moderate Decreased metabolism of Telithromycin caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [61]
Bedaquiline DM3906J Major Decreased metabolism of Telithromycin caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [70]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Posaconazole. Aspergillosis [1F20] [57]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Telithromycin and Levalbuterol. Asthma [CA23] [71]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Telithromycin and Pirbuterol. Asthma [CA23] [71]
Budesonide DMJIBAW Major Decreased metabolism of Telithromycin caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [72]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Telithromycin and Salbutamol. Asthma [CA23] [71]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Telithromycin and Formoterol. Asthma [CA23] [73]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [66]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Desipramine. Attention deficit hyperactivity disorder [6A05] [57]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Retigabine. Behcet disease [4A62] [57]
Cariprazine DMJYDVK Major Decreased metabolism of Telithromycin caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [74]
Erdafitinib DMI782S Major Decreased metabolism of Telithromycin caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [75]
Pexidartinib DMS2J0Z Major Decreased metabolism of Telithromycin caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [76]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Eribulin. Breast cancer [2C60-2C6Y] [57]
Talazoparib DM1KS78 Moderate Decreased clearance of Telithromycin due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [77]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Telithromycin caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [78]
Lapatinib DM3BH1Y Major Decreased metabolism of Telithromycin caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
HKI-272 DM6QOVN Major Decreased metabolism of Telithromycin caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [79]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Telithromycin caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Tucatinib DMBESUA Moderate Decreased metabolism of Telithromycin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [80]
Palbociclib DMD7L94 Major Decreased metabolism of Telithromycin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [81]
Letrozole DMH07Y3 Moderate Decreased metabolism of Telithromycin caused by Letrozole mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Telithromycin caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Telithromycin caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
Bosutinib DMTI8YE Major Decreased metabolism of Telithromycin caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Telithromycin caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
Atorvastatin DMF28YC Major Decreased metabolism of Telithromycin caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [82]
Macitentan DMP79A1 Major Decreased metabolism of Telithromycin caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [83]
PF-04449913 DMSB068 Major Decreased metabolism of Telithromycin caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [84]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Telithromycin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [73]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Telithromycin caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [85]
Revefenacin DMMP5SI Moderate Decreased clearance of Telithromycin due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [86]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Telithromycin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [73]
Dihydrocodeine DMB0FWL Moderate Decreased metabolism of Telithromycin caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [61]
Levomilnacipran DMV26S8 Major Decreased metabolism of Telithromycin caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [87]
Fidaxomicin DMFP6MV Minor Decreased clearance of Telithromycin due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [88]
Anisindione DM2C48U Moderate Decreased metabolism of Telithromycin caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [89]
Regorafenib DMHSY1I Moderate Decreased metabolism of Telithromycin caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [60]
Intedanib DMSTA36 Moderate Decreased clearance of Telithromycin due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [90]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Telithromycin and Isoproterenol. Conduction disorder [BC63] [71]
Drospirenone DM1A9W3 Major Decreased metabolism of Telithromycin caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [60]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Telithromycin caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [61]
Ulipristal DMBNI20 Minor Decreased metabolism of Telithromycin caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [66]
Mestranol DMG3F94 Moderate Decreased metabolism of Telithromycin caused by Mestranol mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [61]
Levobupivacaine DM783CH Moderate Decreased metabolism of Telithromycin caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [61]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Halothane. Corneal disease [9A76-9A78] [57]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Sevoflurane. Corneal disease [9A76-9A78] [57]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Probucol. Coronary atherosclerosis [BA80] [57]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Telithromycin and Pasireotide. Cushing syndrome [5A70] [57]
Osilodrostat DMIJC9X Major Decreased metabolism of Telithromycin caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [91]
Ivacaftor DMZC1HS Major Decreased metabolism of Telithromycin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [60]
Rivaroxaban DMQMBZ1 Major Decreased clearance of Telithromycin due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [60]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Sertraline. Depression [6A70-6A7Z] [57]
Vilazodone DM4LECQ Major Decreased metabolism of Telithromycin caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [92]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Telithromycin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [61]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Telithromycin and Escitalopram. Depression [6A70-6A7Z] [57]
OPC-34712 DMHG57U Major Decreased metabolism of Telithromycin caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [93]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Clomipramine. Depression [6A70-6A7Z] [57]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Doxepin. Depression [6A70-6A7Z] [57]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Telithromycin caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [94]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Telithromycin caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [61]
Oxybutynine DMJPBAX Moderate Decreased metabolism of Telithromycin caused by Oxybutynine mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [61]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [57]
Ospemifene DMC4GEI Moderate Decreased metabolism of Telithromycin caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [95]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Deutetrabenazine. Dystonic disorder [8A02] [96]
Ingrezza DMVPLNC Major Decreased metabolism of Telithromycin caused by Ingrezza mediated inhibition of CYP450 enzyme. Dystonic disorder [8A02] [97]
Cenobamate DMGOVHA Moderate Increased metabolism of Telithromycin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [61]
Fosphenytoin DMOX3LB Major Increased metabolism of Telithromycin caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [66]
Clonazepam DMTO13J Moderate Decreased metabolism of Telithromycin caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [61]
Lacosamide DMVM6QR Moderate Decreased metabolism of Telithromycin caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [60]
Rufinamide DMWE60C Moderate Increased metabolism of Telithromycin caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [61]
Phenobarbital DMXZOCG Major Increased metabolism of Telithromycin caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [66]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Telithromycin caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [61]
Cannabidiol DM0659E Minor Decreased metabolism of Telithromycin caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [66]
Bay 80-6946 DMLOS5R Major Decreased metabolism of Telithromycin caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [98]
Tazemetostat DMWP1BH Major Decreased metabolism of Telithromycin caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [99]
Solifenacin DMG592Q Major Decreased metabolism of Telithromycin caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [60]
Mirabegron DMS1GYT Minor Decreased metabolism of Telithromycin caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [100]
Itraconazole DMCR1MV Major Decreased metabolism of Telithromycin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [61]
Ketoconazole DMPZI3Q Major Decreased metabolism of Telithromycin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [61]
Ripretinib DM958QB Major Decreased metabolism of Telithromycin caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [60]
Sunitinib DMCBJSR Moderate Decreased metabolism of Telithromycin caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [60]
Avapritinib DMK2GZX Major Decreased metabolism of Telithromycin caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [66]
Colchicine DM2POTE Major Decreased metabolism of Telithromycin caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [101]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Telithromycin caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [102]
Boceprevir DMBSHMF Moderate Decreased metabolism of Telithromycin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [103]
ABT-450 DMFW860 Moderate Decreased metabolism of Telithromycin caused by ABT-450 mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [66]
Simeprevir DMLUA9D Major Decreased metabolism of Telithromycin caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [60]
Telaprevir DMMRV29 Moderate Decreased metabolism of Telithromycin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [103]
Daclatasvir DMSFK9V Major Decreased metabolism of Telithromycin caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [66]
GS-9857 DMYU6P5 Moderate Decreased clearance of Telithromycin due to the transporter inhibition by GS-9857. Hepatitis virus infection [1E50-1E51] [104]
Rifampin DMA8J1G Major Increased metabolism of Telithromycin caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [66]
Rifapentine DMCHV4I Major Increased metabolism of Telithromycin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [66]
Brentuximab vedotin DMWLC57 Moderate Decreased metabolism of Telithromycin caused by Brentuximab vedotin mediated inhibition of CYP450 enzyme. Hodgkin lymphoma [2B30] [105]
MK-1439 DM215WE Minor Decreased metabolism of Telithromycin caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [106]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Telithromycin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [107]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Telithromycin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
Dolutegravir DMCZGRE Minor Decreased metabolism of Telithromycin caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [108]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Telithromycin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [109]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [57]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [57]
Atazanavir DMSYRBX Moderate Decreased metabolism of Telithromycin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Maraviroc DMTL94F Major Decreased metabolism of Telithromycin caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [110]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Telithromycin and Mipomersen. Hyper-lipoproteinaemia [5C80] [111]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Telithromycin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [57]
BMS-201038 DMQTAGO Major Decreased metabolism of Telithromycin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [60]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Telithromycin caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [112]
Aliskiren DM1BV7W Moderate Decreased metabolism of Telithromycin caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [57]
Levamlodipine DM92S6N Moderate Decreased metabolism of Telithromycin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [57]
Felodipine DMOSW35 Moderate Decreased metabolism of Telithromycin caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [61]
Tolvaptan DMIWFRL Major Decreased metabolism of Telithromycin caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [60]
Retapamulin DM9JXB7 Minor Decreased metabolism of Telithromycin caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [113]
TP-434 DM5A31S Minor Decreased metabolism of Telithromycin caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [114]
Berotralstat DMWA2DZ Major Decreased clearance of Telithromycin due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [69]
Suvorexant DM0E6S3 Major Decreased metabolism of Telithromycin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [60]
Amobarbital DM0GQ8N Moderate Increased metabolism of Telithromycin caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [102]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Telithromycin caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [115]
Estazolam DMZGXUM Moderate Decreased metabolism of Telithromycin caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [61]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Telithromycin and Polyethylene glycol. Irritable bowel syndrome [DD91] [66]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Telithromycin and Phenolphthalein. Irritable bowel syndrome [DD91] [60]
Naloxegol DML0B41 Major Decreased metabolism of Telithromycin caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [60]
Pemigatinib DM819JF Major Decreased metabolism of Telithromycin caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [116]
Crizotinib DM4F29C Major Decreased metabolism of Telithromycin caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [60]
Brigatinib DM7W94S Major Decreased metabolism of Telithromycin caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [117]
Ceritinib DMB920Z Major Decreased metabolism of Telithromycin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [60]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Telithromycin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [118]
PF-06463922 DMKM7EW Major Decreased metabolism of Telithromycin caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [119]
Osimertinib DMRJLAT Major Decreased metabolism of Telithromycin caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [120]
Pralsetinib DMWU0I2 Major Decreased metabolism of Telithromycin caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [121]
Capmatinib DMYCXKL Major Decreased metabolism of Telithromycin caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [122]
Selpercatinib DMZR15V Major Decreased metabolism of Telithromycin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [123]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Telithromycin and Lumefantrine. Malaria [1F40-1F45] [60]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Telithromycin and Halofantrine. Malaria [1F40-1F45] [60]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Telithromycin and Hydroxychloroquine. Malaria [1F40-1F45] [124]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Primaquine. Malaria [1F40-1F45] [57]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [66]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Telithromycin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [125]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Telithromycin and Idelalisib. Mature B-cell leukaemia [2A82] [126]
GDC-0199 DMH0QKA Major Decreased metabolism of Telithromycin caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [127]
IPI-145 DMWA24P Major Decreased metabolism of Telithromycin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [128]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Telithromycin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [129]
Acalabrutinib DM7GCVW Major Decreased metabolism of Telithromycin caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [130]
Ibrutinib DMHZCPO Major Decreased metabolism of Telithromycin caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [60]
Ponatinib DMYGJQO Major Decreased metabolism of Telithromycin caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [60]
Arry-162 DM1P6FR Moderate Decreased clearance of Telithromycin due to the transporter inhibition by Arry-162. Melanoma [2C30] [60]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Telithromycin and Vemurafenib. Melanoma [2C30] [57]
Selumetinib DMC7W6R Major Decreased metabolism of Telithromycin caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [131]
LGX818 DMNQXV8 Major Decreased metabolism of Telithromycin caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [132]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Telithromycin caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [60]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Telithromycin caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [61]
Ubrogepant DM749I3 Major Decreased metabolism of Telithromycin caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [133]
Rimegepant DMHOAUG Moderate Decreased metabolism of Telithromycin caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [134]
Exjade DMHPRWG Moderate Decreased metabolism of Telithromycin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [135]
Flibanserin DM70DTN Major Decreased metabolism of Telithromycin caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [136]
Panobinostat DM58WKG Major Decreased metabolism of Telithromycin caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [137]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Telithromycin and Thalidomide. Multiple myeloma [2A83] [60]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Telithromycin and Siponimod. Multiple sclerosis [8A40] [60]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Telithromycin and Fingolimod. Multiple sclerosis [8A40] [57]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Telithromycin and Ozanimod. Multiple sclerosis [8A40] [138]
Deflazacort DMV0RNS Major Decreased metabolism of Telithromycin caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [66]
Romidepsin DMT5GNL Moderate Decreased metabolism of Telithromycin caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [139]
Fedratinib DM4ZBK6 Major Decreased metabolism of Telithromycin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [66]
Ruxolitinib DM7Q98D Major Decreased metabolism of Telithromycin caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [140]
Dasatinib DMJV2EK Major Decreased metabolism of Telithromycin caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [60]
Busulfan DMXYJ9C Moderate Decreased metabolism of Telithromycin caused by Busulfan mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [61]
Vorapaxar DMA16BR Major Decreased metabolism of Telithromycin caused by Vorapaxar mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [60]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Promethazine. Nausea/vomiting [MD90] [57]
E-2007 DMJDYNQ Minor Decreased metabolism of Telithromycin caused by E-2007 mediated inhibition of CYP450 enzyme. Neuropathy [8C0Z] [66]
Entrectinib DMMPTLH Major Decreased metabolism of Telithromycin caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [66]
Sibutramine DMFJTDI Moderate Decreased metabolism of Telithromycin caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [61]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Telithromycin and Levomethadyl Acetate. Opioid use disorder [6C43] [66]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Lofexidine. Opioid use disorder [6C43] [57]
S-297995 DM26IH8 Moderate Decreased metabolism of Telithromycin caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [66]
Olaparib DM8QB1D Major Decreased metabolism of Telithromycin caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [60]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Rucaparib. Ovarian cancer [2C73] [57]
MK-4827 DMLYGH4 Moderate Decreased clearance of Telithromycin due to the transporter inhibition by MK-4827. Ovarian cancer [2C73] [141]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Triclabendazole. Parasitic worm infestation [1F90] [57]
Pimavanserin DMR7IVC Major Decreased metabolism of Telithromycin caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [142]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Telithromycin caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [61]
Abametapir DM2RX0I Moderate Decreased metabolism of Telithromycin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [143]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Telithromycin and Macimorelin. Pituitary gland disorder [5A60-5A61] [144]
Lefamulin DME6G97 Major Decreased metabolism of Telithromycin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [105]
Ergonovine DM0VEC1 Major Decreased metabolism of Telithromycin caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [145]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Telithromycin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [146]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Degarelix. Prostate cancer [2C82] [66]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Telithromycin and ABIRATERONE. Prostate cancer [2C82] [66]
Enzalutamide DMGL19D Major Increased metabolism of Telithromycin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [66]
Relugolix DMK7IWL Major Decreased metabolism of Telithromycin caused by Relugolix mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [147]
Darolutamide DMV7YFT Moderate Decreased clearance of Telithromycin due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [148]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Bicalutamide. Prostate cancer [2C82] [66]
Silodosin DMJSBT6 Major Decreased metabolism of Telithromycin caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [60]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Telithromycin caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [149]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Levomepromazine. Psychotic disorder [6A20-6A25] [57]
Ambrisentan DMD1QXW Minor Decreased metabolism of Telithromycin caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [150]
Riociguat DMXBLMP Moderate Decreased clearance of Telithromycin due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [60]
Everolimus DM8X2EH Major Decreased metabolism of Telithromycin caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [60]
Axitinib DMGVH6N Major Decreased metabolism of Telithromycin caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [60]
Temsirolimus DMS104F Major Increased metabolism of Telithromycin caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [60]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Telithromycin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [151]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Telithromycin caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [152]
Upadacitinib DM32B5U Major Decreased metabolism of Telithromycin caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [153]
Tofacitinib DMBS370 Major Decreased metabolism of Telithromycin caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [60]
Dexamethasone DMMWZET Moderate Increased metabolism of Telithromycin caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [61]
Quetiapine DM1N62C Major Decreased metabolism of Telithromycin caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [154]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Telithromycin caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [155]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Telithromycin and Iloperidone. Schizophrenia [6A20] [57]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Paliperidone. Schizophrenia [6A20] [57]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Telithromycin and Amisulpride. Schizophrenia [6A20] [156]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Asenapine. Schizophrenia [6A20] [57]
Pimozide DMW83TP Major Decreased metabolism of Telithromycin caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [157]
Avanafil DM75CXN Major Decreased metabolism of Telithromycin caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [60]
Voxelotor DMCS6M5 Major Decreased metabolism of Telithromycin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [158]
LDE225 DMM9F25 Major Decreased metabolism of Telithromycin caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [159]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Telithromycin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [66]
Larotrectinib DM26CQR Major Decreased metabolism of Telithromycin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [60]
Docetaxel DMDI269 Major Decreased clearance of Telithromycin due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [160]
Trabectedin DMG3Y89 Major Decreased metabolism of Telithromycin caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [60]
Armodafinil DMGB035 Minor Decreased metabolism of Telithromycin caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [60]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Telithromycin and LEE011. Solid tumour/cancer [2A00-2F9Z] [161]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Telithromycin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [57]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [66]
Taxol DMUOT9V Moderate Decreased metabolism of Telithromycin caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [162]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [57]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Pitolisant. Somnolence [MG42] [66]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [57]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Telithromycin caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [60]
Fostamatinib DM6AUHV Major Decreased metabolism of Telithromycin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [163]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Telithromycin due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [164]
As-1670542 DMV05SW Moderate Decreased metabolism of Telithromycin caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [66]
Apixaban DM89JLN Major Decreased metabolism of Telithromycin caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [60]
Brilinta DMBR01X Major Decreased metabolism of Telithromycin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [60]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Lenvatinib. Thyroid cancer [2D10] [57]
Cabozantinib DMIYDT4 Major Decreased metabolism of Telithromycin caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [60]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Telithromycin and Papaverine. Tonus and reflex abnormality [MB47] [165]
Saxagliptin DMGXENV Moderate Decreased metabolism of Telithromycin caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [66]
Elagolix DMB2C0E Major Decreased metabolism of Telithromycin caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [166]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [57]
Fluticasone DMGCSVF Major Decreased metabolism of Telithromycin caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [167]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Telithromycin and Procainamide. Ventricular tachyarrhythmia [BC71] [168]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Propafenone. Ventricular tachyarrhythmia [BC71] [57]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Telithromycin and Flecainide. Ventricular tachyarrhythmia [BC71] [57]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Telithromycin and Amiodarone. Ventricular tachyarrhythmia [BC71] [168]
⏷ Show the Full List of 257 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Telithromycin 300 mg tablet 300 mg Oral Tablet Oral
Telithromycin 400 mg tablet 400 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr Opin Microbiol. 2005 Oct;8(5):510-7.
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47.
9 Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet. 2005;44(9):915-34.
10 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
11 Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci. 2010 Sep 11;41(1):86-95.
12 Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother. 2006 Apr;7(6):639-51.
13 Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother. 2005 Feb;39(2):357-60.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
24 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
25 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
26 Drug Interactions Flockhart Table
27 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
28 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
29 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
30 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
31 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
32 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
33 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
34 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
35 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
36 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
37 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
38 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
39 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
40 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
41 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
42 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
43 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
44 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
45 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
46 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
47 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
48 A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54.
49 Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
50 Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98.
51 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
52 Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5.
53 Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7.
54 The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9.
55 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
56 The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol. 2002 Sep 13;322(2):273-9.
57 Canadian Pharmacists Association.
58 Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1. [PMID: 8781892]
59 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
60 Cerner Multum, Inc. "Australian Product Information.".
61 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
62 Product Information. Cleocin (clindamycin). Pharmacia and Upjohn, Kalamazoo, MI.
63 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
64 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
65 Multum Information Services, Inc. Expert Review Panel.
66 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
67 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
68 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
69 Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90. [PMID: 6882885]
70 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
71 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
72 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
73 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
74 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
75 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
76 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
77 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
78 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
79 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
80 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
81 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
82 Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
83 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
84 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
85 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
86 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
87 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
88 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
89 Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36. [PMID: 14769198]
90 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
91 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
92 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
93 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
94 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
95 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
96 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
97 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
98 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
99 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
100 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
101 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
102 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
103 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
104 Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Gilead Sciences, Foster City, CA.
105 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
106 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
107 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
108 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
109 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
110 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
111 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
112 Product Information. Sensipar (cinacalcet). Amgen USA, Thousand Oaks, CA.
113 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
114 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
115 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
116 Product Information. Pemazyre (pemigatinib). Incyte Corporation, Wilmington, DE.
117 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
118 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
119 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
120 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
121 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
122 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
123 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
124 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
125 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
126 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
127 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
128 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
129 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
130 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
131 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
132 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
133 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
134 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
135 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
136 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
137 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
138 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
139 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
140 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
141 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
142 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
143 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
144 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
145 Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8. [PMID: 8607732]
146 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
147 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
148 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
149 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
150 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
151 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
152 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
153 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
154 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
155 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
156 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
157 Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
158 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
159 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
160 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
161 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
162 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
163 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
164 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
165 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
166 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
167 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
168 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]